Evidence suggests an advantage for TBI over BU as a component of conditioning regimens for allogeneic hematopoietic cell transplant in patients with ALL. We have employed both TBI and BU for conditioning in ALL and reviewed our experience to compare outcomes. From July 1989 to June 2008, we identified 86-adult ALL patients treated with either a TBI-or BU-based regimen and transplanted with either a well-matched sibling or unrelated donor. Data including demographics, immunophenotype, disease status and cytogenetic risk were examined by Cox proportional hazards analysis. Patients treated with TBI were older (median age 40 vs 33 years; P ¼ 0.018), had a higher-risk cytogenetic profile (P ¼ 0.010), were more often transplanted using an unrelated donor (P ¼ 0.038) and were treated more recently (Po0.001). There was a significant improvement in EFS (P ¼ 0.046), and a trend to improved OS (P ¼ 0.08) in patients treated with TBI compared with those treated with BU. However, the advantage for TBI could not be confirmed by multivariable analysis where only disease status retained statistical significance.
Introduction
Allogeneic hematopoietic cell transplant (AHCT) is the only treatment capable of curing relapsed ALL and is the most effective treatment to prevent relapse in patients in first remission. 1 Conditioning regimens for myeloablative AHCT generally include either TBI or BU. An early report found no difference in outcome between TBI-and BUbased regimens in ALL in CR1, but demonstrated better 2-year leukemia-free survival for TBI-based regimens (34 vs 14%; P ¼ 0.002) in patients with advanced disease. 2 A retrospective study of 156 patients with ALL treated with autologous or allogeneic HCT found an increased risk for relapse (71 vs 47%; P ¼ 0.01) and lower 6-year PFS (22 vs 43%; P ¼ 0.01) in patients treated with BU. 3 Another retrospective study of 221 patients with ALL treated with AHCT also found improved disease-free survival for patients treated with TBI compared with BU (26 vs 17%; P ¼ 0.04). 4 The 5-year OS was 30% for patients treated with TBI and 17% for patients treated with BU (P ¼ 0.041). Multivariable analysis indicated that conditioning with TBI was associated with improved survival compared with BU (hazard ratio 0.79; 95% confidence interval 0.64-0.97; P ¼ 0.027). Based on these retrospective observations, most centers employ TBI rather than BU in conditioning regimens for AHCT in patients with ALL.
Our institution initially treated ALL patients with BUbased regimens for AHCT. A 3-year leukemia-free survival rate of 42% was reported for patients in first remission, first relapse or second remission, with BU plus CY (BUCY). 5 Patients with advanced disease were reported to have only a 10-20% leukemia-free survival with BUCY or BUCY plus VP-16 (BUCYVP). 6, 7 Accumulated data from other centers favoring TBI conditioning in ALL prompted us to switch from BU-based regimens to TBI for AHCT conditioning in patients with ALL. We reviewed our experience with both approaches to determine whether outcomes improved with TBI.
Patients and methods

Patients
A total of 115 patients aged X18 years with ALL underwent AHCT at the Cleveland Clinic from July 1989 to June 2008. The diagnosis of ALL was made by histologic and immunophenotypic review of the initial diagnostic BM aspirate specimen. Cytogenetic analysis was performed according to accepted standards. Cytogenetic-risk groups were assigned according to Cancer and Leukemia Group B (CALGB) criteria. 8 All patients had normal hepatic, renal, pulmonary and cardiac function before AHCT. Patients with a history of leukemic meningitis were required to demonstrate normal spinal fluid cytology before AHCT. All patients signed an informed consent document approved by the Cleveland Clinic Institutional Review Board.
Preparative regimens
We treated our first patient with BU in July 1989. The first regimen used included BU 16 mg/kg and CY 120 mg/kg. To improve cytoreduction, a more intensive regimen of BU 14 mg/kg, CY 120 mg/kg and VP-16 50 mg/ kg was subsequently employed. The last ALL patient treated with BU was in June 2002. Subsequent patients received 1200 cGY with a testicular boost plus etoposide 60 mg/kg. We excluded one patient from the BU group whose preparative regimen was not BUCY or BUCYVP and two from the TBI group whose preparative regimen was not TBI/VP.
Donor selection
Serologic typing for HLA-A, B, Cw, DR and DQ was performed by standard lymphocytotoxicity assays from peripheral blood samples. HLA-DRB1* and DQB1* typings were performed by PCR sequence-specific oligonucleotide probing or direct sequencing. For sequence-specific oligonucleotide probing assays, extracted DNA was PCR amplified using exon 2-specific primers and hybridized with oligonucleotide probes obtained from commercial sources (Lifecodes Corporation, Stamford, CT, USA or One Lambda, Canoga Park, CA, USA) according to the manufacturer's instructions.
In cases performed since May 1999, HLA-A*, B* and Cw* DNA-based typings were performed by PCR sequence-specific priming using commercial kits (Pel-Freez, Brown Deer, WI, USA), PCR sequence-specific oligonucleotide probing using oligonucleotide probes based on those used in the International Histocompatibility Workshops or commercial kits (One Lambda) according to the manufacturer's instructions, or direct sequencing of exons 2-and 3-amplified products as previously described.
Patient-donor pairs were classified as well matched, partially matched or mismatched according to the criteria set forth by the Center for International Blood and Marrow Transplant Research (CIBMTR). 9 To simplify the analysis and to remove potential biases created by mismatched donor pairs, we selected only well-matched sibling and unrelated donors for full analysis.
GVHD prophylaxis
Patients were treated with CYA 3 mg/kg/day or tacrolimus 0.03 mg/kg/day as a continuous i.v. infusion plus either MTX 5 mg/m 2 i.v. on days 1, 3, 6 and 11 or mycophenolate 500 mg p.o t.i.d. Patients treated with TBI also received methylprednisolone. Five patients treated with TBI were also treated with extracorporeal photophoresis as part of a clinical trial.
We conducted a study of CD8 þ T-cell depletion and treated 16 of the 86 evaluable patients with ALL on this protocol (14 treated with BU and 2 treated with TBI). The T-cell depletion process has been previously described. 10 
Supportive care
All patients were managed in a dedicated BM transplant unit in laminar airflow rooms with standard infection control procedures. All patients received G-CSF daily until neutrophil recovery beginning either the day after marrow infusion in patients not receiving prophylactic MTX, or on day 12 after MUD BMT in patients treated with MTX. All patients received weekly i.v. gammaglobulin while hospitalized, then at least monthly until 100 days after BMT.
Patient evaluation
Initial engraftment was defined as a sustained ANC of greater than 500/mL. Graft failure was defined as failure to achieve an ANC greater than 500/mL Graft rejection was defined as an unexplained, sustained decrease in the ANC to less than 500/mL after initial engraftment. Acute and chronic GVHDs were diagnosed clinically with histologic confirmation whenever possible.
Statistical evaluation
Baseline characteristics were compared between preparative regimens using the t-test or w 2 -test. OS and EFS were calculated relative to the transplant date. The event corresponding to OS is all-cause mortality; events corresponding to EFS are graft rejection, graft failure, relapse or all-cause mortality. OS and EFS were estimated using the Kaplan-Meier method and compared between preparative regimens using the log-rank test. Non-relapse mortality, relapse mortality and sites of initial relapse were estimated using cumulative incidence methodology and compared between preparative regimens using the Pepe-Mori test. Cox proportional hazards analysis was used to identify univariable and multivariable prognostic factors for OS and EFS. For the primary multivariable analysis, models included age and variables that were significant at Pp0.10 in univariable analysis. As a secondary multivariable analysis, stepwise Cox models were utilized with a variable entry criterion of Pp0.10 and a variable retention criterion of Pp0.05. A total of 11 variables were analyzed as potential prognostic factors: gender, age, immunophenotype, cytogenetics, disease status at transplant, timing (year) of transplant, conditioning regimen, source of hematopoietic cells, T-cell depletion, donor relationship and donor/recipient CMV status. Data were analyzed using SAS software (SAS Institute Inc., Cary, NC, USA). All statistical tests were two sided, and Pp0.05 was used to indicate statistical significance.
Results
From July 1989 to June 2008, 115 adult ALL patients underwent AHCT. From these 115 patients, we excluded 21 patients with donors who were not well matched; 3 patients with well-matched, related, non-sibling donors; 2 patients treated with cord blood transplants; and 3 patients who were not treated with our common conditioning regimens. The remaining 86 had well-matched sibling or well-matched unrelated donors and were treated with BUCY, BUCYVP or TBI. There were no outcome differences between BUCY and BUCYVP (P ¼ 0.39 (OS); P ¼ 0.21 (EFS)), although the small number of patients treated with BUCY prohibits detection of anything other than large differences. For the remainder of this analysis, the 51 patients treated with BU are considered together. The characteristics of the 86 patients treated with either BU or TBI regimens are described in Table 1 .
In univariable analysis, EFS was better among patients transplanted with a TBI-based preparative regimen (P ¼ 0.046) compared with regimens containing BU. There was also a trend toward improved OS with TBI (P ¼ 0.08) (Figure 1 ). For the subgroup of 56 patients treated in either CR1 or CR2, there was no statistically significant advantage in either EFS or OS for TBI in the conditioning regimen (P ¼ 0.11 and P ¼ 0.20, respectively).
There was no significant difference in incidence or severity of GVHD or survival in the patients treated with T-cell depletion compared with the other patients (data not shown) and they are therefore included in this analysis. A higher percentage of BU patients were T-cell depleted (28 vs 6%; P ¼ 0.011).
Patients treated with TBI had a higher median age (40 vs 33 years; P ¼ 0.018), more poor-risk cytogenetics (66 vs 30%; P ¼ 0.010) and more unrelated donors (40 vs 20%; P ¼ 0.038) than the BU group. Despite these differences, there was no significant difference in the cumulative incidence of either acute or chronic GVHD in patients treated with TBI compared with those treated with BU (P ¼ 0.56 and P ¼ 0.63, respectively).
The incidence of initial relapse in an extramedullary site following BU-based AHCT was 50%, but only 9% following TBI (P ¼ 0.005). However, there was no higher relapse mortality (P ¼ 0.87) in patients treated with BU. The use of BU trended to a higher incidence of non-relapse mortality that did not reach significance (P ¼ 0.09).
The risk of either CMV infection or viremia was less in the population of patients treated with BU compared with those treated with TBI (19.6 vs 60%; P ¼ 0.01). As expected, though, the risk of sinusoidal obstructive syndrome was higher in the patients treated with BU (9.8 vs 0%; P ¼ 0.026). However, there was no significant difference in the incidence of secondary malignancies after treatment in either cohort (P ¼ 0.99).
Univariable analysis for factors predictive of EFS identified disease status at transplant and preparative regimen as significant variables, whereas factors predictive of OS identified only disease status at transplant. In multivariable modeling adjusted for age and the variables identified as prognostic in univariable analysis, only disease status retained significant predictive ability for OS and marginally for EFS (Table 2) . A stepwise selection model identified only disease status as a significant predictor of poor OS and EFS. Neither conditioning regimen, cytogenetic-risk group, nor age, were significantly associated with survival.
As only disease status was predictive of outcome by multivariable analysis that included all patients, OS and EFS were compared between preparative regimens in the subset of patients in CR1 or CR2 and the subset of patients in CR1. OS and EFS did not differ between preparative regimens for either subset of patients.
Discussion
BU is an important component of several conditioning regimens for AHCT. Regimens containing BU result in similar outcomes to those achieved with TBI-based regimens in patients with myeloid malignancies, including CML and AML. Based on comparative retrospective studies in adults, and prospective, randomized studies in children, however, TBI, and not BU, has become the standard for AHCT for patients with ALL. 11, 12 Our singleinstitution study, adjusted for age and other known prognostic factors, could not confirm a significant benefit of TBI in EFS or OS compared with BU. However, TBI did reduce the incidence of extramedullary relapse.
A much larger German study of SCT for ALL found a significant survival advantage for patients treated with TBI conditioning. 4 In their multivariable analysis, TBI was a significant predictive factor for disease-free survival, even though the most predictive factor was also disease status. Furthermore, this study found no significant difference in outcome between sibling and unrelated donors, and did not include the degree of HLA matching in the analysis. We limited our study to those with well-matched siblings and well-matched unrelated donors to reduce the effects of mismatching on outcome and found no significant benefit to TBI.
A Spanish analysis of 90 patients with ALL treated with AHCT from matched sibling donors found a 3-year EFS of 43% in patients treated with TBI compared with 22% in patients treated with BU (P ¼ 0.01). 3 This study included children, for whom randomized trials also demonstrated an advantage for TBI-based regimens. 13, 14 In the Spanish study, multivariable analysis also identified age greater than 16 years as an adverse predictor of outcome. Our analysis found no significant impact of age or conditioning regimen on either EFS or OS in an adult population.
The study populations in our investigation were not balanced for potential risk factors. For example, the TBI-treated cohort was older and included a higher percentage of cases with poor risk cytogenetics. Even though we could not demonstrate an effect on outcome, more than a quarter of the patients treated with BU were also treated with CD8 þ T-cell depletion. More patients treated with TBI were transplanted from an unrelated donor. In aggregate, these disparities would tend to favor the BU-treated cohort and thus could explain our inability to demonstrate a significant advantage for TBI. When we accounted for the disparities in our two treatment cohorts by multivariable analysis, the only significant prognostic risk factor was disease status.
We found a significant difference in the pattern of relapse between our patients treated with BU and those treated with TBI. There was less risk of extramedullary relapse in patients treated with TBI. The finding of a higher risk of CMV infection or viremia in patients treated with TBI more likely reflects modern surveillance of CMV with molecular monitoring techniques rather than a reflection of greater infectious risk. However, the finding of an increased risk of sinusoidal obstructive syndrome in the population of patients treated with BU was not unexpected. 15 Interestingly, there was no significant difference in the risk of GVHD or secondary malignancies in the two treatment arms. Our retrospective study is relatively small and suffers from the large time interval over which patients were treated. Supportive care and patient selection changed over time and these changes are not fully accounted for in our analysis. Despite these limitations, our study has the advantage of long follow-up at a center experienced with BU conditioning. Our study suggests that any survival advantage for TBI compared with BU as a conditioning regimen for well-matched AHCT in patients with ALL is modest when accounting for other prognostic factors.
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